Study of vamifeport for adults with iron overload from hereditary hemochromatosis
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This study tests an investigational drug called vamifeport to see if it can reduce iron levels in the body and improve outcomes for people with hereditary hemochromatosis (a genetic condition causing too much iron absorption). Participation may help manage iron overload and potentially reduce the need for regular blood removal treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of hereditary hemochromatosis (specifically the HFE type).
- You must have iron overload, shown by blood tests (TSAT > 45% and ferritin between 200 and 5000 ng/mL) and an MRI of the liver showing iron levels in a specific range.
- Your body mass index (BMI) must be between 18.5 and 34.9.
- You must not have other significant medical conditions or abnormal test results that could affect your safety or the study results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether intravenous (IV) iron therapy can help older adults who have heart failure with preserved pumping function and low iron levels. It aims to improve symptoms and quality of life.
This trial tests an experimental drug called BBI-001. It first looks at safety in healthy volunteers, then tests whether it can help people with hereditary hemochromatosis, a condition where the body stores too much iron.
This study tests whether intravenous (IV) iron can help people with pulmonary hypertension feel better, have more energy, and enjoy a better quality of life. You may qualify if you have a type of pulmonary hypertension and low iron levels.
This study checks how common iron deficiency is in people with HFpEF (heart failure with preserved pumping strength) and tests whether an iron infusion (Ferinject®) improves health. It targets people with stable heart symptoms and lab results showing low iron stores or related iron deficiency.
This study tests whether giving intravenous iron improves symptoms, quality of life, and exercise ability in people with heart failure and low iron levels. Participants will receive iron infusions and be monitored over time to see if their condition improves.
This study tests whether giving iron through a vein can improve mobility and musculoskeletal (muscle and joint) function in older adults with iron-deficiency anemia. It may help people feel stronger and move better if their anemia is caused by low iron.
Hear when a new Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.